Search

Your search keyword '"Riley, Unell"' showing total 6 results
Start Over Author "Riley, Unell" Search Limiters Full Text
6 results on '"Riley, Unell"'

2. An Early CT-Diagnosis Based Treatment Strategy for Invasive Fungal Infection in Allogeneic Transplant Recipients Using Caspofungin First Line: An Effective Strategy with Low Mortality.

Author

Dignan, Fiona L, primary, Evans, Stephen O, primary, Ethell, Mark E, primary, Shaw, Bronwen E., primary, Riley, Unell BG, primary, Davies, Faith, primary, Treleaven, Jennifer G., primary, Dearden, Claire E., primary, Morgan, Gareth J., primary, and Potter, Michael N, primary

Published
2008
Full Text
View/download PDF

6. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.

Author

Dungarwalla M, Evans SO, Riley U, Catovsky D, Dearden CE, and Matutes E

Subjects
Adult, Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Murine-Derived, Antimetabolites, Antineoplastic administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Humans, Infection Control, Infections etiology, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Male, Methylprednisolone adverse effects, Methylprednisolone pharmacology, Middle Aged, Rituximab, Vidarabine administration & dosage, Vidarabine pharmacology, Antibodies, Monoclonal therapeutic use, Antimetabolites, Antineoplastic pharmacology, Antineoplastic Agents therapeutic use, Immunotherapy adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Methylprednisolone therapeutic use, Salvage Therapy, Vidarabine analogs & derivatives
Abstract

The combination of high dose methylprednisolone and rituximab induces superior overall (93%) and complete (14%) response rates compared to high dose methylprednisolone alone (overall 43%, complete remission 0%) in heavily pre-treated chronic lymphocytic leukemia patients with advanced disease. Despite its efficacy the combination is not easily manageable because of the high rate of opportunistic infections.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results